利妥昔单抗在间质性肺病中的使用进展
Progress in the use of rituximab in interstitial lung disease
间质性肺病(interstitial lung disease,ILD)作为结缔组织病(connective tissue diseases, CTD)较为严重的肺部并发症,传统药物治疗疗效欠佳。近年来,生物制剂等治疗方式的运用,改善了此类患者的预后状况。利妥昔单抗(rituximab,RTX)是特异性针对 B 淋巴细胞表面 CD20 抗原的人鼠嵌合单克隆抗体。临床实践显示,RTX 可作为糖皮质激素及免疫抑制治疗失败的多种结缔组织相关性间质性肺病(connective tissue dis-ease-related interstitial lung disease, CTD-ILD)患者有价值的治疗选择。本文对 RTX 的作用机制及其在 CTD-ILD 中的应用进行综述。
Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases (CTD), and conventional pharmacotherapy yields unsatisfactory therapeutic outcomes. In recent years, the application of therapeutic approaches such as biologics has improved the prognosis of such patients. Rituximab (RTX) is a chimeric human-mouse monoclonal antibody specifically targeting the CD20 antigen on the surface of B lymphocytes. Clinical practice has demonstrated that RTX serves as a valuable therapeutic option for patients with various connective tissue disease-related interstitial lung disease (CTD-ILD) who fail glucocorticoid and immunosuppressive therapy. This article reviews the mechanism of action of RTX and its application in connective tissue disease-associated ILD.
| [1] |
|
| [2] |
|
| [3] |
邢楠舒, 张榕. 生物制剂及小分子靶向药物治疗 CTD-ILD[J].中华临床免疫和变态反应杂志, 2020, 14(5): 495-499. |
| [4] |
Weiner GJ. Rituximab: mechanism of action[J].Semin Hematol, 2010, 47(2): 115-123. |
| [5] |
|
| [6] |
|
| [7] |
霍荣秀, 郭乾育, 许珂. 药物治疗结缔组织病相关间质性肺疾病的进展[J].中华风湿病学杂志, 2022, 26(7): 489-493. |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Sugiyama Y, Yoshimi R, Tamura M, |
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Fujikawa K, Kawakami A, Kaji K, |
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
Atkins SR, Turesson C, Myers JL, |
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
Fassio A, Sebastiani M, Pollastri F, |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
中国初级卫生保健基金会风湿免疫学分会干燥综合征和 IgG4 相关性疾病专委会, 系统性红斑狼疮专委会. 利妥昔单抗治疗风湿免疫病中国专家共识 (2024 版)[J].中华风湿病学杂志, 2024, 28(8): 521-537. |
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
Benham H, Garske L, Vecchio P, |
| [47] |
|
| [48] |
Arulkumaran N, Periselneris N, Gaskin G, |
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
国家科技重大专项(2023ZD0506305)
/
| 〈 |
|
〉 |